HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-04-07FDA Approved: VIREAD — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for VIREAD (tenofovir disoproxil fumarate) from Gilead Sciences, Inc.
-
FDA approval · 2017-04-07FDA Approved: COMPLERA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for COMPLERA, a fixed-dose combination therapy for HIV-1 infection developed by Gilead Sciences.
-
FDA approval · 2017-04-07FDA Approved: STRIBILD — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for STRIBILD, a fixed-dose combination HIV-1 therapy from Gilead Sciences.
-
FDA approval · 2017-04-07FDA Approved: ODEFSEY — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for ODEFSEY (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide) from Gilead Sc…
-
FDA approval · 2017-04-07FDA Approved: EMTRIVA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for EMTRIVA (emtricitabine) from Gilead Sciences.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-04-07FDA Approved: EMTRIVA — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for EMTRIVA (emtricitabine) from Gilead Sciences, Inc.
-
FDA approval · 2017-04-07FDA Approved: DESCOVY — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for DESCOVY (emtricitabine and tenofovir alafenamide) from Gilead Sciences, Inc.
-
FDA approval · 2017-03-28FDA Approved: ABACAVIR AND LAMIVUDINE — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' generic fixed-dose combination tablet of abacavir and lamivudine. It is indicated for the treatment of H…
-
FDA approval · 2017-03-28FDA Approved: ABACAVIR AND LAMIVUDINE — Original Application (Cipla USA Inc.)
FDA approved Cipla USA Inc.'s abacavir and lamivudine as a generic fixed-dose combination tablet for the treatment of HIV-1 infection in com…
-
FDA approval · 2017-03-27FDA Approved: TIVICAY — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for Tivicay (dolutegravir) submitted by ViiV Healthcare Company. This action updates the regulat…
-
FDA approval · 2017-03-27FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for TRIUMEQ, a fixed-dose combination antiretroviral therapy.
-
FDA approval · 2017-03-20FDA Approved: ZIAGEN — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for Ziagen (abacavir sulfate) filed by ViiV Healthcare Company. This action updates the labeling…
-
FDA approval · 2017-02-24FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for RETROVIR (zidovudine) filed by ViiV Healthcare, indicating an update to the drug's labeling …
-
FDA approval · 2017-02-24FDA Approved: COMBIVIR — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for Combivir (lamivudine and zidovudine) submitted by ViiV Healthcare Company.
-
FDA approval · 2017-02-24FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for Retrovir (zidovudine) submitted by ViiV Healthcare Company.
-
FDA approval · 2017-02-24FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for RETROVIR (zidovudine) submitted by ViiV Healthcare Company.
-
FDA approval · 2017-02-15FDA Approved: GENVOYA — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) filed by Gilead Sci…
-
FDA approval · 2017-01-27FDA Approved: EVOTAZ — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
The FDA approved a supplemental application for EVOTAZ (atazanavir and cobicistat) submitted by E.R. Squibb & Sons, L.L.C. The action involv…
-
FDA approval · 2016-12-22FDA Approved: NORVIR — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for NORVIR (ritonavir) submitted by AbbVie Inc.
-
FDA approval · 2016-12-20FDA Approved: TIVICAY — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for Tivicay (dolutegravir sodium) submitted by ViiV Healthcare Company.
-
FDA approval · 2016-12-14FDA Tentative Approval: LAMIVUDINE — Supplemental Application (Strides Pharma Science Limited)
FDA issued tentative approval for Strides Pharma Science Limited's generic lamivudine under an ANDA, signaling potential US market approval …
-
FDA approval · 2016-12-07FDA Tentative Approval: TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Strides Pharma Science Limited)
FDA granted tentative approval for Strides Pharma Science Limited's generic Tenofovir Disoproxil Fumarate. The product is considered bioequi…
-
FDA approval · 2016-12-07FDA Approved: GENVOYA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) submitted by Gi…
-
CLINICAL_TRIALS approval · 2016-11-30Clinical Trial Update: Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection
Tipranavir has received marketing approval for HIV infection in patients with progressive systemic HIV-1 disease who have failed or are into…
-
CLINICAL_TRIALS approval · 2016-11-30Clinical Trial Update: Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection
Tipranavir has been approved for marketing for HIV-1 infection in protease inhibitor-experienced patients.